WHO Pharmaceuticals Newsletter No. 3, 2015

OMS, 4 de julio de 2015

Contenido

Asuntos regulatorios

Agomelatine ................................................................................... .....5

Amiodarone and hepatitis C treatments containing sofosbuvir ..................... .........5

Amphetamines and methylphenidate ............................................................7

Asunaprevir and daclatasvir hydrochloride ..................................................... 7

Azilsartan ............................................................................................7

BioCSL Fluvax® .....................................................................................8

Cefotaxime sodium ................................................................................8

Clopidogrel sulphate containing medicines .....................................................8

Codeine-containing medicines ...................................................................8

Cyclophosphamide hydrate .......................................................................9

Duloxetine hydrochloride.......................................................................... 9

Epoetin beta.................................................................................... ...10

Ferumoxytol  .................................................................................... ..10

Hydroxyzine-containing medicines ............................................................. 11

Methylphenidate ................................................................................. .11

Non-steroidal anti-inflammatory drugs and diclofenac ..................................12

Oral ibuprofen ................................................................................12

Panitumumab................................................................................. 13

Panitumumab and cetuximab .............................................................. 13

Pazopanib hydrochloride ...................................................................14

Pomalidomide ................................................................................14

Rebamipide (Ophthalmic solution) ........................................................14

Sevoflurane....................................................................................15

Sitagliptin phosphate hydrate ............................................................. 15

Triamcinolone acetonide ...................................................................15

Seguridad de medicamentos

Capecitabine and folic acid .............................................................. 17

Ceftolozane and tazobactam ............................................................. 17

Ceftriaxone and calcium containing diluents ............................................17

Clozapine with another antipsychotic drugs ............................................18

Dimethyl fumarate ......................................................................... 18

Flurbiprofen-containing topical pain medications ......................................19

Goldenseal (Hydrastis canadensis).........................................................19

Guaifenesin ..................................................................................20

Hydroxyzine .................................................................................20

Olanzapine pamoate ....................................................................... 21

Señales

Prucalopride and Suicidal ideation .......................................................22

Vemurafenib and Thrombocytopenia ....................................................27

Feature

Strengthening pharmacovigilance in countries: a brief report from two WHO events ....................................................................................... .......35

Dsiponible en http://bit.ly/1H4liQ9